Exhibit 99.1
TENTH AMENDMENT TO FACILITY AGREEMENT
ThisTENTH AMENDMENT TO FACILITY AGREEMENT (this “Amendment”) dated as of September 26, 2018, is by and among MannKind Corporation, a Delaware corporation (the “Borrower”), MannKind LLC, a Delaware limited liability company (the “Guarantor,” and together with the Borrower collectively, the “Obligors”), Deerfield Private Design Fund II, L.P. (“DPDF”) and Deerfield Private Design International II, L.P. (“DPDI” and, together with DPDF, the “Purchasers”). Capitalized terms used herein which are defined in the Facility Agreement (as defined below), unless otherwise defined herein, shall have the meanings ascribed to them in the Facility Agreement.
RECITALS:
A. The Obligors and the Purchasers have entered into that certain Facility Agreement, dated as of July 1, 2013, as amended by the First Amendment to Facility Agreement and Registration Rights Agreement, dated as of February 28, 2014, the Second Amendment to Facility Agreement, dated as of August 11, 2014, the Exchange and Third Amendment to Facility Agreement, dated as of June 29, 2017, the Fourth Amendment to Facility Agreement (the “Fourth Amendment”), dated as of October 23, 2017, the Fifth Amendment to Facility Agreement (the “Fifth Amendment”), dated as of January 15, 2018, the Exchange and Sixth Amendment to Facility Agreement (the “Sixth Amendment”), dated as of January 18, 2018, the Exchange and Seventh Amendment to Facility Agreement (the “Seventh Amendment”), dated as of June 8, 2018, the Exchange and Eighth Amendment to Facility Agreement (the “Eighth Amendment”), dated as of July 12, 2018 and the Ninth Amendment to Facility Agreement (the “Ninth Amendment”), dated as of September 5, 2018 (as the same may be further amended, modified, restated or otherwise supplemented from time to time, the “Facility Agreement”).
B. The Facility Agreement provides for the issuance of Notes in 4 Tranches of $40,000,000 per Tranche. Prior to the date hereof, the Purchasers have purchased the Tranche 1 Notes, the Tranche 2 Notes, the Tranche 3 Notes and the Tranche 4 Notes in the aggregate principal amount of $40,000,000 per Tranche.
C. The Facility Agreement also provides for the issuance of Tranche B Notes. An aggregate of $20,000,000 in principal amount of Tranche B Notes have been issued to the Purchasers.
D. Prior to the date hereof, (i) the Purchasers have converted all of the Tranche 2 Notes and the Tranche 3 Notes into Common Stock and (ii) the Borrower has repaid, converted, exchanged and/or otherwise satisfied a portion of the principal amounts under the Tranche 1 Notes, Tranche 4 Notes and Tranche B Notes, leaving $5,000,000 in principal amount of the Tranche 1 Notes, $6,995,000 in principal amount of the Tranche 4 Notes and $2,500,000 in principal amount of the Tranche B Notes outstanding.
E. On September 3, 2018, the Borrower entered into an exclusive global license and collaboration agreement (the “License Agreement”) with United Therapeutics Corporation (“UT”). The License Agreement provides, among other things, that (i) the Borrower will receive from UT an upfront payment (the “UT Upfront Payment”) of $45 million within 10